^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pilaralisib (SAR245408)

    i
    Company:
    Exelixis, Sanofi
    Drug class:
    PI3K inhibitor
    Related drugs:
    Apply
    Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen (NCT01042925)
    Phase 1/2
    Sanofi
    Completed
    Last update posted :
    06/03/2016
    Initiation :
    02/01/2010
    Primary completion :
    12/01/2012
    Completion :
    12/01/2012
    HER-2
    |
    HER-2 positive • HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • pilaralisib (SAR245408) • AP06 (trastuzumab biosimilar)
    Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer (NCT01082068)
    Phase 1/2
    Sanofi
    Completed
    Last update posted :
    06/03/2016
    Initiation :
    06/01/2010
    Primary completion :
    04/01/2013
    Completion :
    04/01/2013
    HER-2
    |
    letrozole • pilaralisib (SAR245408) • voxtalisib (SAR245409)